肿瘤细胞治疗研究
英文原题：From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives.
嵌合抗原受体（CAR）T细胞疗法被设想为一种重定向效应T细胞以消除肿瘤细胞的机制。
嵌合抗原受体（CAR）T细胞疗法被设想为一种重定向效应T细胞以消除肿瘤细胞的机制。CAR由结合天然癌症抗原的抗体可变区与TCR的信号结构域及共刺激分子偶联而成。其成功及获得美国食品药品监督管理局批准用于治疗B细胞恶性肿瘤，彻底改变了免疫治疗领域，促使人们广泛研究其可能应用于其他癌症类型。在这篇综述中，我们将聚焦于CAR-T细胞疗法的演变，概述当前技术及其广泛应用的主要障碍。我们将重点介绍已取得的成就、为提高疗效并发展为现货型治疗所做的努力，以及作为非癌症相关疾病潜在未来治疗手段的可能性。
Chimeric antigen receptor (CAR) T-cell therapy was envisioned as a mechanism to re-direct effector T-cells to eliminate tumor cells. CARs are composed of the variable region of an antibody that binds a native cancer antigen coupled to the signaling domain of a TCR and co-stimulatory molecules. Its success and approval by the U.S. Food and Drug Administration for the treatment of B-cell malignancies revolutionized the immunotherapy field, leading to extensive research on its possible application for other cancer types. In this review, we will focus on the evolution of CAR-T cell therapy outlining current technologies as well as major obstacles for its wide application. We will highlight achievements, the efforts to increase efficacy and to evolve into an off-the-shelf treatment, and as a possible future treatment for non-cancer related diseases.
MEMBER ACCOUNT
登录成功会直接打开下一页。
